estradiol tablet
avpak - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 0.5 mg
estradiol tablet
avera mckennan hospital - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 1 mg
estradiol tablet
actavis pharma, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 0.5 mg
estradiol tablet
pd-rx pharmaceuticals, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 1 mg
estradiol tablet
cardinal health - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 1 mg
estradiol tablet
avera mckennan hospital - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 0.5 mg
estrogel estradiol (as hemihydrate) 0.06% w/w gel pump pack
besins healthcare australia pty ltd - estradiol hemihydrate, quantity: 0.06 % w/w (equivalent: estradiol, qty 0.06 % w/w) - gel - excipient ingredients: carbomer 980; trolamine; ethanol; purified water - - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women.,- prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. (see also section 4.4 special warnings and precautions for use),the experience treating women older than 65 years is limited. the lowest effective dose should be used for the shortest duration (see sections 4.2 dose and method of administration and 4.4 special warnings and precautions for use).
estradiol tablet
bryant ranch prepack - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol tablets are indicated in the: 1. treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribed solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4. treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. 5. treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). 6. prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate (see clinical pharmacology, clinical studies .) the mainstays for decreasing the
estradiol tablet
nucare pharmaceuticals, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol tablets are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. - treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). - prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (see clinical pharmacology , clinical studies. ) - the m
estradiol- estradiol tablet
lake erie medical dba quality care products llc - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol tablets are indicated in the: 1. treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribed solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4. treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. 5. treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). 6. prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate (see clinical pharmacology, clinical studies .) the mainstays for decreasing the